S.C.P.C - Annual Report 2023 | FinancialReports.eu

==> picture [445 x 235] intentionally omitted <==

Standard Chem & Pharm Co., Ltd. Stock Symbol : 1720 2024 Investor Conference 4/25/2024

==> picture [280 x 75] intentionally omitted <==

免責聲明 Safe Harbor Notice

==> picture [88 x 81] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何
事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.

We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2024 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2023 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2024 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2023 Operating Results  Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

==> picture [842 x 475] intentionally omitted <==

----- Start of picture text -----

SCP and Related/Affiliated Com nies
pa
Upstream Manufacture Channels
Syn-Tech (1982; 2005
SCP(1967;
Taiwan Biosim(2017)
Over-The-Counter (OTC))
Western 1995 listed stock)
medicine
Your Chance
Syngen(1999; 2016 OTC) Souriree(1997)
(Invested in 2013;
2024.03 OTC)
Syngen(1999)
Healthcare Multipower
nutrition (Invested in 2012)
Sun-you(1994)
Medical- Syngen (1999)
devices
Q
Ho Yao Biopharm (2021)
Obtained CRO certification In October 2023
4
© 2024 SCP, Ltd
----- End of picture text -----

International Accreditation

==> picture [606 x 32] intentionally omitted <==

----- Start of picture text -----

1998 2000 2008 2009 2010 2017 2021
----- End of picture text -----

==> picture [42 x 45] intentionally omitted <==

==> picture [29 x 38] intentionally omitted <==

The first TW pharmaceutical company to be ISO9001 certified

==> picture [50 x 32] intentionally omitted <==

==> picture [46 x 25] intentionally omitted <==

The first TW company to pass US FDA inspection in 2000

Subsequent US FDA GMP inspections : no 483 Last Inspection : 2022/10/31

==> picture [28 x 37] intentionally omitted <==

SCP received JP PMDA’s “Certificate of Foreign Drug Manufacturer” in 2008

FDF Plant and API Plant passed PMDA GMP Audit in 2018

==> picture [50 x 31] intentionally omitted <==

==> picture [58 x 37] intentionally omitted <==

2009

==> picture [48 x 33] intentionally omitted <==

SCP’s API plant passed AU TGA inspection

==> picture [44 x 34] intentionally omitted <==

==> picture [48 x 36] intentionally omitted <==

2010 SCP passed TW PIC/S GMP inspection 2012 SCP is certified GDP by the T-FDA

==> picture [49 x 33] intentionally omitted <==

==> picture [70 x 31] intentionally omitted <==

2012 SCP passed K-FDA inspection

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2024 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2023 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

6
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Consolidated Income Statement

Items	2023	2022	Diff.	Annual changes (%)
(Unless otherwise specified, expressed in thousands of New Taiwan Dollars)
Operating revenue	6,239,768	5,851,368	388,400	6.6%
Gross profit	2,725,378	2,487,613	237,765	9.6%
Gross profit margin	43.68%	42.51%		1.17%
Operating expenses	1,465,826	1,369,192	96,634	7.1%
Operating profit	1,259,552	1,118,421	141,131	12.6%
Non-operating income and expenses	178,315	281,512	(103,197)	-36.7%
Profit before income tax	1,437,867	1,399,933	37,934	2.7%
Profit for the year	1,157,929	1,153,620	4,309	0.4%
Profit attributable to Shareholders of the parent	834,886	815,408	19,478	2.4%
EPS(NTD)	4.67	4.56	0.11	2.4%
2024 SCP, Ltd

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 2024 Expressed in thousands of NTD 19 20 21 22 23 19 20 21 22 23 19 20 2122 19 20 21 22 23 23 24	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 2024 Expressed in thousands of NTD 19 20 21 22 23 19 20 21 22 23 19 20 2122 19 20 21 22 23 23 24	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 2024 Expressed in thousands of NTD 19 20 21 22 23 19 20 21 22 23 19 20 2122 19 20 21 22 23 23 24	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 2024 Expressed in thousands of NTD 19 20 21 22 23 19 20 21 22 23 19 20 2122 19 20 21 22 23 23 24	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 2024 Expressed in thousands of NTD 19 20 21 22 23 19 20 21 22 23 19 20 2122 19 20 21 22 23 23 24	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 2024 Expressed in thousands of NTD 19 20 21 22 23 19 20 21 22 23 19 20 2122 19 20 21 22 23 23 24	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 2024 Expressed in thousands of NTD 19 20 21 22 23 19 20 21 22 23 19 20 2122 19 20 21 22 23 23 24
	Q1	Q2	Q3	Q4	Total	Growth(%)
2019	846,177	1,010,837	1,048,886	1,031,229	3,937,129	+10.2%
2020	1,034,417	1,108,059	1,045,351	1,117,573	4,305,400	+9.4%
2021	1,101,113	1,149,060	1,120,840	1,233,069	4,604,082	+6.9%
2022	1,237,170	1,481,061	1,549,872	1,583,265	5,851,368	+27.1%
2023	1,493,025	1,509,004	1,645,531	1,592,208	6,239,768	+6.6%
2024(Per book)	1,613,344				1,613,344	+8.06%

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Consolidated Balance Sheet

Items	2023	2023	2022	2022	Diff.	Annual changes(%)
(Expressed in thousands of NTD)	Amount	%	Amount	%
Cash and cash equivalents	2,036,743	18.2%	2,259,381	20.6%	(222,638)	(9.9%)
Accounts receivable	1,418,423	12.7%	1,479,581	13.5%	(61,158)	(4.1%)
Inventories	1,614,976	14.4%	1,386,483	12.6%	228,493	16.5%
Investments	1,206,522	10.8%	1,184,109	10.8%	22,413	1.9%
Property, plant and equipment	4,021,526	35.9%	3,658,581	33.4%	362,945	9.9%
Others	890,534	8.0%	1,000,124	9.1%	(109,590)	(11.0%)
Total Assets	11,188,724	100.0%	10,968,259	100.0%	220,465	2.0%
Current Liabilities	2,370,880	21.2%	2,879,832	26.3%	(508,952)	(17.7%)
Non-current Liabilities	680,507	6.1%	652,826	6.0%	27,681	4.2%
Total liabilities	3,051,387	27.3%	3,532,658	32.2%	(481,271)	(13.6%)
Total shareholder’s equity	8,137,337	72.7%	7,435,601	67.8%	701,736	9.4%
Debt Ratio(Liabilities/Assets)		27.3%		32.2%
© 2024 SCP, Ltd

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Consolidated Cash Flows

==> picture [88 x 81] intentionally omitted <==

Items	2023	2022
(Expressed in thousands of NTD)
Cash at beginning ofyear	2,259,381	2,564,395
Cash flows from operatingactivities	1,336,523	1,227,834
Acquisition ofproperty,plant and equipment	(625,696)	(1,196,056)
Cash dividends	(446,740)	(446,740)
Short & long-term borrowings	(450,003)	124,014
Investment and others	(36,722)	(14,066)
Cash at end ofyear	2,036,743	2,259,381

Free cash flow (Cash flows from operating activities-Acquisition of property, plant and equipment)	710,827	31,778

==> picture [88 x 81] intentionally omitted <==

SCP (Code:1720) achieved a record high net profit after tax EPS and cash dividend in 2023 ,

NTD Thousand

==> picture [811 x 355] intentionally omitted <==

----- Start of picture text -----

900,000 4.56 [4.67] 5.00
4.50
800,000
3.95
4.00
700,000
3.50
600,000
2.93
3.00
500,000
2.50
400,000 2.09 [2.15 ] 2.09 1.95 1.90 2.03 2.09 2.11
1.77 [1.81 1.88 ]
2.00
300,000 1.35 [1.47 1.61 1.73 ]
1.50
2.50 2.70
2.50
200,000
1.20 [1.50] [1.25] 1.20 [1.60] 0.50 1.00 1.20 1.00 1.50 1.50 1.60 1.50 1.50 1.80 1.00 Q
100,000 2.50 0.50
0.70
0.30 0.30
0 0.00
11
© 2024 SCP, Ltd
----- End of picture text -----

SYN-TECH’s (Code:1777) net profit after tax and EPS in 2023

NTD Thousand

© 2024 SCP, Ltd 0 50,000 100,000 150,000 200,000 250,000 300,000 350,000	0.50 1.70 2.00 2.40 1.52 1.00 2.30 1.00 1.30 2.00 3.00 3.50 3.50 1.75 3.30 3.50 4.00 1.93 3.00 3.50 2.93 3.33 1.74 2.37 2.15 3.38 2.19 1.89 3.10 4.935.20 5.27 1.99 5.125.31 6.21 5.03 6.62 5.63 0 1 2 3 4 5 6 7 8 9

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Syngen’s(Code:8279) net profit after tax and EPS in 2023

NTD Thousand

==> picture [655 x 307] intentionally omitted <==

----- Start of picture text -----

400,000 14.00
11.85
350,000
12.00
10.14
300,000
10.00
8.77
250,000 7.86 7.95
8.00
6.43
200,000
5.8
6.00
4.69
150,000
3.76
4.00
5.00
100,000
3.50
2.04 4.00
2.00
50,000
1.00 1.00 2.50
3.00
0.50
0.00 1.00 5.00
0 0.00
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2024 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group  2023 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

Future Milestone

==> picture [697 x 88] intentionally omitted <==

==> picture [115 x 147] intentionally omitted <==

From Taiwan to International From Generics to Better than Generics (BTG)

==> picture [263 x 68] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

	Significant Business Activities in Recent Years	Significant Business Activities in Recent Years	Significant Business Activities in Recent Years

	Taiwan	China	Japan
	• Double-digit growth in	• Antibiotic injections	• Continues to be sold of
	clinic and hospital. • Southeast Asia region’s sales growth. • Establishment of marketing team for Philippines subsidiary. • Record-high revenue and profits in 2023.	continue to be sold • Technology transfer certificate:2 cases. • Consistency Evaluation(GQCE) reviews in progress :3 cases. • Under R&D:4cases.	2 medications: bronchiolitis and oral anti-inflammatory and pain relief medications. • The new contracted CDMO: 1 case. • Acting as importer for gout new medicines, nasal spray generic
			medicines, with a submission scheduled	Q
			for 2023 and expected
©	2024 SCP, Ltd		to get the license in 2025.	16

Revenue Growth Strate -Taiwan gy

==> picture [127 x 181] intentionally omitted <==

SCP (1720) 4.67 S n-Tech 1777 5.63 y ( ) S n en 8279 10.14 y g ( )

We Can (6929) 0.37

Outstanding performance
Specializing in four key areas:
- Western medicines, APIs, health supplements, and pharmaceutical chain stores.
SCP, Syn-Tech, Syngen, and Your Chance boast exceptional management teams.
We Can has been listed on the OTC since March 28, 2024.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

17
----- End of picture text -----

China Market Trends: Current

Continuously improve the national centralized drug procurement system.
Medical reform Strengthen regular supervision of the use of medical insurance funds.
in 2024 • Increase the per capita fiscal subsidy standard for resident medical insurance.
Deepen reforms in public hospitals.
Profit Margin Compression: The expansion and acceleration of centralized
Challenges in procurement, along with negotiations on medical insurance and rising raw the material prices, are squeezing profit margins. •
pharmaceutical Expansion of the CDMO (Contract Development and Manufacturing Organization) Market: The global market share of the CDMO market The global market share of the CDMO market
field
Expansion of the CDMO (Contract Development and Manufacturing Organization) Market: The global market share of the CDMO market The global market share of the CDMO market increased from 5% in 2017 to 13% in 2021, with an estimated increase to 20% by 2025.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [815 x 474] intentionally omitted <==

----- Start of picture text -----

China Market Trends: Current
•
In mid-December 2022, China ended its "zero-COVID" policy, causing a rebound
in pharmaceutical sales. In the first half of 2023, pharmaceutical sales gradually
stabilized.
(Unit: Hundred million/RMB)
16000 Hospital Drugstore Overall sales
14084
13824 13816
14000 13329
12961
12000
10984
10387 10465 10210
9717
10000
8000 7384
6000 5564
Q
4000 2942 3100 3244 3359 3606
1820
2000 Source：
www.menet.com.cn
19
China (public hospital and
0 b rick-and-mortar
© 2024 SCP, Ltd 2018 2019 2020 2021 2022 2023 H1 pharmacy)
----- End of picture text -----

Revenue Growth Strate - China gy

==> picture [72 x 71] intentionally omitted <==

Strategy

==> picture [67 x 54] intentionally omitted <==

Achievements in getting licenses

Own brand and tech transfer simultaneously
2 cases for tech transfer
CDMO
Expand the number of collaborative projects and pharmaceutical companies

==> picture [70 x 68] intentionally omitted <==

NMPA Consistency Evaluation

==> picture [71 x 73] intentionally omitted <==

3 cases submitted for evaluation

Medium-term targets

Self-developed products submission
Tech transfer profit sharing revenue

Project initiation/Research in progress

Cooperation

Tech-transfer
4 cases in progress
Joint ownership of License
Cooperative production and marketing
Profit-sharing Partnerships

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Ja an Market Trend-Generic Dru s Market in 2023 p g

There are only 176 generic drugs applying for drug prices in 2023, which is 18% of that in 2020 and a record low. It is speculated that generic pharmaceutical companies will gradually reduce the launch of . new products to ensure stable supply Only 16 ingredients are the first generic drug . The launch of the first generic drug is the main source of revenue for pharmaceutical companies, and the decline in the number of applications is not conducive to future operations.

==> picture [6 x 32] intentionally omitted <==

==> picture [6 x 31] intentionally omitted <==

(Number Changes in price application items for generic drugs of items) The first generic drug application Others (Year, Month)

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 113] intentionally omitted <==

----- Start of picture text -----

Q
21
----- End of picture text -----

Japan Market Trend-Drug price system reform in 2024

==> picture [6 x 32] intentionally omitted <==

The PMDA is undergoing institutional reforms to address two major issues: drug shortages and supply instability.

Encouraging new drugs and similar pharmaceuticals to enter the market more readily.

Adjust the method of drug price weighting.
Increase weighted assessment criteria.
Expand assessment for pediatric medication.
Recalculate drug prices to attract similar products into the market.

Ensure stable supply of generic drugs.

Ensuring stable supply system for enterprises is one of the factors considered in drug price adjustments.
When there are 10 or more generic drug pricing applications, the price of generic drugs is .
set at 0.4 of the original drug price, reduced to 7 or more applications
Essential drugs with a market presence of 25 years and high medical necessity may not undergo price reduction adjustments. This period is shortened to 15 years.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

22
----- End of picture text -----

Revenue Growth Strate - Ja an gy p

==> picture [71 x 63] intentionally omitted <==

==> picture [67 x 64] intentionally omitted <==

Strategy

Collaboration Model

Agent for brand new drugs.
CDMO
Collaborating with Japan pharmaceutical company to enter other markets.
Japan marketing partner
Self-owned license
Strategic alliance with API manufacturer.
API Vertical Integration with Syn-Tech.

==> picture [69 x 65] intentionally omitted <==

----- Start of picture text -----

•
•
----- End of picture text -----

Current State

On Going

2 items continue sales
1 new signed CDMO collaboration
CDMO/CMO
Common items for China/ Southeast Asia/ Japan are under discussion
Acting as an agent for a new gout medication and nasal spray generic drug, registration is in progress.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

US Market Trend-The shortage of medicines is becoming increasingly serious

The US market is facing a severe shortage of approximately 132 small molecule drugs, including those for pain/anesthesia, oncology, central nervous system, and infectious diseases. Generic drugs (84%) and injectable medications (67%) are among those affected.
Factors contributing to the shortages include natural disasters and interruptions in the supply of raw materials.
Shortages of GLP-1 medications for diabetes and weight loss are on the rise, primarily due to increased demand. Since the launch of Wegovy (Semaglutide) in 2021, new prescriptions for diabetes GLP-1 have increased by 181%, and new prescriptions for obesity GLP-1 have increased by 257%. New data shows that GLP-1 therapy can prevent cardiovascular events, which may further increase demand.
According to the ASHP Drug Shortage Database, shortages have been reported for Semaglutide, Tirzepatide, Liraglutide, and Dulaglutide.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

24
----- End of picture text -----

US Market Trend-Develo ment in Future p

==> picture [6 x 32] intentionally omitted <==

The greatest contributors to growth in the next five years will be oncology, immunology, diabetes, and obesity drugs. This growth is a result of continuous influx of innovative medications.

==> picture [552 x 240] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

25
----- End of picture text -----

Revenue Growth Strate – U.S.A. gy

==> picture [154 x 110] intentionally omitted <==

U.S.A. Market

Application process for drug licenses is costly, time-consuming, and requires longterm planning
Target products with patents expiring in 5 years or more.
Increase the number of sales items and cooperating manufacturers.

==> picture [54 x 53] intentionally omitted <==

Strategy

Co-develop new products with pharmaceutical companies and dealers.

Current Status

Passed the fifth FDA inspection in 2022.
Strategic alliances with raw material suppliers
Shipped three drugs: for diabetes, spinal muscular atrophy, and lipidlowering.
API Vertical Integration with Syn-Tech.
Actively participated in exhibitions to expand business.
Seeking Early Market Entry for First to File.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

Future Operation Strategy

2024 2025 、 Southeast Asia 、、 USA Japan China Japan

Future From Taiwan to International From Generics to BTG

Core techniques and Increasing oversea professional Oversea marketing Resource proportion 增加海核心技術 skills to expend & 專業海外市場操作 practices oversea sales 借力使力 • 外比例 • • Increase resources for Use mature Taiwanese Establish a solid foundation. overseas business.

Use mature Taiwanese technology to create R&D wealth.
Quickly generate revenue.
Recruit and train international talents.
Learn the rules of the game. in various markets.
Jointly plan and operate in various markets. markets with foreign • Seek for long-term partners.
companies.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

27
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group  2023 Operating Results  Future Operation Strategy

 Corporate Social Responsibility (CSR)

Net Zero Emissions and Sustainable Develo ment p

Energy Management

Waste Management

Engage qualified environmental service providers and recycling businesses certified by the Environmental Protection Agency to carry out cleaning and treatment or resource reuse.
• Submit a waste cleanup plan in accordance with the law, implement it after review and approval. Select waste transporters and treatment facilities with legal registration and Class A licenses.
Replacing T5 fluorescent lights with LED lights, resulting in an annual electricity savings of approximately 24,960 kWh.
• Upgraded our ventilation system, replacing with variable frequency blowers, saving 295,650 kWh of electricity per year.
Inventory classification management reduces waste, saving 91,980 kWh per year.
Implementing maintenance, recycling hot water, adjusting system parameters, optimizing water production conditions, etc., effectively reduce carbon emissions, improve costeffectiveness, and save energy.
Conducting periodic maintenance of pipelines to reduce unnecessary water loss due to leaks.
• Regularly disclosing Company's water usage to remind employees to conserve water resources.
• Optimizing the production process and product design to reduce unnecessary water usage while improving production efficiency.

Water Resource Management

Prioritizing the use of water-saving equipment

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Social Care and EngagementFan Dao Nan Foundation

==> picture [156 x 115] intentionally omitted <==

Introduction to the foundation

Established in 1987
Endowment Fund: NT$196 Million
Annual Budget: NT$12 Million

==> picture [157 x 113] intentionally omitted <==

Principal Activities

Cultural and educational development activities
Public education affairs
Children’s education and happiness
Scholarships and Talent Cultivation

==> picture [158 x 114] intentionally omitted <==

Rewards and Honors Received

2011: Special Recognition Award – Ministry of Education
2012: Tainan City Govt. Grant for Scholarship Program
2013: National Special Selection Award for
After-School Program – Dept. of Education
2022: Group Award on Social Education Contribution by Ministry Of Education

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [806 x 474] intentionally omitted <==

----- Start of picture text -----

Social Care and Engagement-2023 Corporate
Social Responsibility
Scholarships
Hope After-school Class Sunflower Wednesdays
 Pharmaceutical or related major: 3
universities/ 7 students
High school :8 schools, totaled 133 •Weekday afternoons •Every Wednesday afternoons
students
Middle school:56 schools, totaled •16 schools，1,050 students •4 Schools，230 students
719 students
 Elementary school: 239 schools,
totaled 2,800 students
NTD 1.16 million NTD 0.15 million
NTD 6.61 million
Other Sponsorships Meal-Assistance Charity
 organizations.Sponsor 12 public welfare  Provided 8,280 meals  SCP Children’s Drawing Competition
NTD0.39 million
 SCP National Table Tennis Q
Competition NTD1.88 million
NTD 0.68 million NTD 0.74 million NTD 2.27 million
31
© 2024 SCP, Ltd
----- End of picture text -----

Social Care and Engagement-The 38[th] SCP National Table Tennis Com etition p

From December 1st, 2023, the tournament was held for three consecutive days at the Tainan Municipal Xinying Stadium.
A record high of 344 teams and 2,172 participants competed.

==> picture [190 x 284] intentionally omitted <==

==> picture [416 x 248] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

- - Social Care and Engagement Senior Gym Athletic Training and Health Center

==> picture [150 x 189] intentionally omitted <==

==> picture [234 x 175] intentionally omitted <==

==> picture [251 x 173] intentionally omitted <==

2023

==> picture [236 x 166] intentionally omitted <==

Accumulated a total of 127,098 user times.
Held 19 health and wellness seminars and fitness courses, providing knowledge on nutritional care, muscle strengthening exercises, and senior fitness courses.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [236 x 475] intentionally omitted <==

Q & A

==> picture [88 x 81] intentionally omitted <==

AI assistant

S.C.P.C — Annual Report 2023

51900_rns_2024-04-24_d759b2ef-7c5f-4b5b-be46-2953ddace241.pdf

免責聲明 Safe Harbor Notice

Agenda

Agenda

International Accreditation

Agenda

Consolidated Income Statement

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

Consolidated Balance Sheet

Consolidated Cash Flows

SCP (Code:1720) achieved a record high net profit after tax EPS and cash dividend in 2023 ,

NTD Thousand

SYN-TECH’s (Code:1777) net profit after tax and EPS in 2023

NTD Thousand

Syngen’s(Code:8279) net profit after tax and EPS in 2023

NTD Thousand

Agenda

Future Milestone

Revenue Growth Strate -Taiwan gy

China Market Trends: Current

Revenue Growth Strate - China gy

Strategy

Achievements in getting licenses

Medium-term targets

Cooperation

Ja an Market Trend-Generic Dru s Market in 2023 p g

Japan Market Trend-Drug price system reform in 2024

Revenue Growth Strate - Ja an gy p

Strategy

Collaboration Model

Current State

On Going

US Market Trend-The shortage of medicines is becoming increasingly serious

US Market Trend-Develo ment in Future p

Revenue Growth Strate – U.S.A. gy

U.S.A. Market

Strategy

Current Status

Q

Future Operation Strategy

Agenda

Net Zero Emissions and Sustainable Develo ment p

Energy Management

Waste Management

Water Resource Management

Social Care and EngagementFan Dao Nan Foundation

Introduction to the foundation

Principal Activities

Rewards and Honors Received

© 2024 SCP, Ltd

Social Care and Engagement-The 38[th] SCP National Table Tennis Com etition p

- - Social Care and Engagement Senior Gym Athletic Training and Health Center

2023

Q & A

More from S.C.P.C

S.C.P.C Annual Report 2023